Pacific Biosciences of California (NasdaqGS:PACB) FY Conference November 19, 2025 11:00 AM ET Company ParticipantsJim Gibson - CFOConference Call ParticipantsNone - Analyst 1None - Analyst 2None - Analyst 3ModeratorAll right. We can start a minute or two later.Jim GibsonSure.Are you guys doing a Q&A style thing, or what do you guys say?I have some prepared. If you guys have questions, I mean, absolutely hop in. Do you?I mean, I've got some stuff I'd like to know. I don't know. It's up to you. I'm just kind ...

Pacific Biosciences of California (NasdaqGS:PACB) 2025 Conference November 18, 2025 08:40 AM ET Company ParticipantsJim Gibson - CFODoug Shankle - Head of Tools, Diagnostics and LabsDoug ShankleHey, everybody. I'm Doug Shankle from Wolfe Research. I lead our tools, diagnostics, and labs effort here. It's my pleasure to welcome Jim Gibson, Chief Financial Officer of Pacific Biosciences. Thanks for being here, Jim.Jim GibsonOf course. My pleasure. Always love coming to New York.Doug ShankleWe were talking abo ...

PacBio Q3 2025 Earnings Presentation November 5, 2025 Third Quarter 2025 Earnings Call This presentation contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, statements relating to PacBio's costs and initiatives as well as the expected financial impact and ti ...

Core Insights - PacBio has introduced new SPRQ-Nx sequencing chemistry aimed at providing a comprehensive view of the genome for under $300, significantly reducing costs for large-scale operations by up to 40% [2][3] - The advancements include multiomic capabilities and compliance features for regulated research environments, enhancing the accessibility of HiFi sequencing for various applications [2][4] Cost Reduction and Technology Advancements - The new SPRQ-Nx chemistry allows for sequencing costs to drop to less than $300 per genome, with beta testing set to begin in November 2025 and full commercial availability planned for 2026 [2][3] - Beta participants will have the opportunity to purchase sequencing reagents for approximately $250 per genome, making it the most affordable option in the market [3] Multiomic and Epigenetic Capabilities - The updates include 5hmC detection for epigenetic profiling, which will be integrated into the Vega platform alongside the SPRQ-Nx chemistry in 2026 [2][4] - These enhancements are designed to support high-demand applications, including rapid sequencing runs for plasmid and targeted sequencing [4] Market Demand and Future Support - There is an increasing demand for HiFi data in large-scale population studies, with PacBio committing to long-term support for the Revio and Vega platforms through 2032 [5] - The company anticipates that the new pricing structure will enable researchers to leverage HiFi data for a broader range of applications, particularly those requiring large sample sizes for robust AI models [4][5]

Summary of Pacific Biosciences of California (PACB) FY Conference Call - August 12, 2025 Company Overview - **Company**: Pacific Biosciences of California (PACB) - **Conference Date**: August 12, 2025 - **Key Focus**: Discussion of Q2 results and future outlook Key Points Financial Performance - Q2 revenue reached **$39.8 million**, slightly exceeding expectations and aligning with internal forecasts [3] - **60%** of placements were with new customers, indicating strong demand for long-read sequencing technology [3] - **45% growth** in revenue from the rest of the world, particularly in EMEA and Asia Pacific [3] - Continued improvement in gross margins quarter over quarter, attributed to better yields from smart cells [3] Cash Flow and Guidance - Reduced cash burn in Q2, with expectations for further reductions in the second half of the year [4] - Targeting cash flow positivity by the end of **2027** [4] - Guidance range refined due to increased confidence in the second half of the year, despite uncertainties related to NIH funding and tariffs in China [9][10] Market Dynamics - EMEA anticipated to be the strongest growth region, with significant progress in PopGen studies and hospital collaborations [5] - Modest pull-ahead in orders from China, primarily for consumables, impacting revenue stability [6][7] - U.S. academic customers showed continued spending on consumables, but larger budget allocations remain uncertain [11] Product Insights - The **Revio** instrument is seen as a key driver for future financial performance, although sales to academic customers have been lower than expected [14][12] - The company is diversifying its customer base beyond academia, focusing on biopharma and clinical markets [18] - Anticipated launch of **multi-use smart cells** expected to lower costs per genome and improve gross margins [34][35] Clinical Market Expansion - Clinical business now accounts for **15%** of consumables, with potential for significant growth as labs adopt PacBio technology [25][26] - Revio's introduction has reduced the cost per genome to approximately **$500**, making it more competitive in clinical settings [29][46] - Future growth expected from partnerships with labs like GeneDx and Varyontics, although significant revenue contributions are not anticipated until later years [31][32] Strategic Focus - Emphasis on improving gross margins through better supply chain management and product offerings [51] - The company is pivoting towards consumables and multi-use products in response to a challenging macroeconomic environment [56][58] - Long-term vision includes leveraging AI and advanced data analytics to enhance the value of PacBio's sequencing data [59] Risks and Considerations - Ongoing uncertainties regarding U.S. academic funding and potential impacts on sales forecasts [10][12] - The need for clarity in the funding environment to drive future sales of high-value instruments like Revio [13] Conclusion Pacific Biosciences is navigating a complex market landscape with a focus on expanding its customer base, improving product offerings, and achieving cash flow positivity by 2027. The company is optimistic about its growth potential in clinical markets and the impact of new technologies on its financial performance.

Financial Performance - PacBio Q1 2025 revenue was $37.2 million[9,43], a decrease of 8% year-over-year compared to $38.8 million in Q1 2024[47] - Q1 2025 consumable revenue reached a company record of $20.1 million, representing a 26% year-over-year growth[14] - The company's Q1 2025 non-GAAP gross margin was approximately 40%, an increase from approximately 33% in Q1 2024[50] - Non-GAAP operating expenses for Q1 2025 were $61.7 million, a 29% decrease compared to Q1 2024[50] - PacBio anticipates revenue between $150 million and $170 million for 2025, representing approximately 4% growth at the midpoint[20,55] Product and System Updates - Q1 instrument revenue was $11.0 million, lower year-over-year due to increased uncertainty in academic funding[9] - PacBio shipped 12 Revio systems and 28 Vega systems in Q1 2025[9] - Approximately 50% of Revio and Vega systems were shipped to new customers[9,28] - The annualized Revio pull-through for Q1 2025 was $236,000[14,43] - Nearly 90% of Revio reagent kit shipments in Q1 2025 utilized SPRQ chemistry[23] Strategic Initiatives - PacBio implemented a restructuring plan in April, expecting to lower annualized non-GAAP operating expenses by $45 million to $50 million by year-end[21]

Core Insights - PacBio has licensed advanced deep learning-based DNA methylation detection methods from The Chinese University of Hong Kong (CUHK) to enhance its HiFi sequencing capabilities, specifically for detecting 5-hydroxymethylcytosine (5hmC), hemimethylated 5-methylcytosine (5mC), and N6-methyladenine (6mA) [1][2][4] Technology and Innovation - The licensed technology includes the Holistic Kinetic Model 2 (HK2), which utilizes an AI deep learning framework to improve the accuracy of methylation detection, including the ability to call native 5hmC in single molecules, a first for HiFi sequencing [2][4] - HiFi sequencing on Revio and Vega platforms allows for comprehensive genome and epigenome readouts from native DNA without chemical conversion or additional sample preparation, enhancing the efficiency of sequencing workflows [3][6] Market Impact - The integration of HK2 is expected to set a new standard for accuracy in DNA methylation detection, particularly for 5mC and 5hmC, which are crucial for research in cancer and human development [4][7] - Institutions like Children's Mercy Kansas City and GeneDx are already utilizing HiFi sequencing for genomic and epigenomic profiling, indicating a growing adoption of this technology in clinical settings [5] Future Prospects - The new capabilities from HK2 will be delivered to existing customers through software updates, ensuring no additional costs or changes to current sequencing protocols [3][8] - The ability to profile 5hmC is anticipated to open new avenues in liquid biopsy and cancer detection, maintaining DNA integrity and supporting haplotype-resolved analysis [6][8]